William M. Grady, MD


William M. Grady, MD

Translational Science and Therapeutics Division, Fred Hutch

Public Health Sciences Division, Fred Hutch

Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch

Fax: 206.667.2917
Mail Stop: G4-100

Dr. William “Bill” Grady identifies new ways to prevent, detect and treat colon cancer and other gastrointestinal, or GI, cancers. His research centers on molecular markers of disease, called biomarkers, that are easily accessible in blood or stool samples. A molecular biologist, Dr. Grady identifies biomarkers that eventually could be used in widely available tests to detect cancer early, when it is most treatable, or even identify healthy tissues at high risk of becoming cancerous. With such methods, doctors could tailor cancer prevention tests and therapies to those who need them the most. Dr. Grady is a leader of national research groups in his field. He is also a gastroenterologist who cares for patients with GI cancers and precancers and people with genetic conditions that increase their risk of developing GI cancers.

Other Appointments & Affiliations

Medical Director, Gastrointestinal Cancer Prevention Program
Fred Hutchinson Cancer Center

Rodger C. Haggitt Professor, Division of Gastroenterology
University of Washington School of Medicine


University of Michigan – Ann Arbor, 1990, MD

University of Michigan – Ann Arbor, 1987, BS

Research Interests

Molecular and cell biology of gastrointestinal cancer

Genetic and epigenetic alterations in cancer

Cancer biomarkers

Hereditary cancer syndromes

Clinical Studies

ColoCare cohort study: Prospective cohort study of people with colorectal cancer. The goal of the study is to identify factors (lifestyle, molecular features of the cancer, etc) that affect prognosis.

GLNE007: A validation and comparison of biomarkers for the early detection of colorectal adenocarcinoma. Using a population of 6000 participants at 10-20 sites across the US and Canada, this study will validate stool, serum and urine biomarkers for colorectal cancer. The biomarker test results are compared to clinical screening or surveillance colonoscopy to see if they can detect adenomas >1cm, high grade dysplasia and adenocarcinoma.

GICaRes study: Study of factors that affect the health and disease of the gastrointestinal tract using clinically annotated biospecimens from people undergoing screening tests for GI cancer.

Laboratory Based Studies

Identify and Validate Novel Epigenetic Molecular Markers for Colorectal Neoplasm

Genetic Determinants of Barrett’s Esophagus and Esophageal Adenocarcinoma

Novel Biomarkers for the Prevention and Treatment of Colon Cancer


"Our best chance to find better ways to prevent and cure cancer is through partnerships between physicians, scientists and patients."

— Dr. William Grady

Find a Clinical Trial Led by Dr. Grady

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210